Skip to Content Facebook Feature Image

Aon Projects Southeast Asia Salary Increases to Remain Stable at 5.2% in 2027

Asia Pacific

Aon Projects Southeast Asia Salary Increases to Remain Stable at 5.2% in 2027
Asia Pacific

Asia Pacific

Aon Projects Southeast Asia Salary Increases to Remain Stable at 5.2% in 2027

2026-09-23 14:00 Last Updated At:14:16

SINGAPORE – Media OutReach Newswire – 23 September 2026 – Aon plc (NYSE: AON), a leading global professional services firm, projects that organisations across Southeast Asia are budgeting for salary increases of 5.2% in 2027, up from 5% in 2026 according to findings from its 2026 Salary Increase and Turnover Study for Southeast Asia.

Overall, Indonesia and Vietnam are expected to record the highest salary increases in the region at 5.5% and 6.7% respectively. At the industry level, projected salary increases vary across markets reflecting differing economic conditions, labour market dynamics and sector-specific demand across the region. The retail and hospitality industry is expected to have the highest increase in Singapore at 4.8%, while the life sciences and medical devices industry leads in Malaysia at 5.2%, Thailand, at 5.3% and Vietnam at 7.7%. The consulting, business and community services industry leads in the Philippines at 6.7%.

"Boardrooms face important decisions on how to allocate investment in technology and talent while navigating an uncertain environment fraught with emerging and interconnected risks," said Rahul Chawla, Partner and Head of Talent Solutions, Southeast Asia, Aon. "Persistent inflation and ongoing skill shortages are directing investments toward the roles and skills that will drive returns on their broader business investments. While competitive pay remains important, organisations must also consider the broader employee value proposition including growth opportunities, purpose and career development to create opportunities for long-term organisational growth."

Country Salary Increase in 2025 (%) Salary Increase in 2026 (%) Projected (Budgeted) Salary Increase in
2027 (%)
Attrition in 2024 (%) Attrition in 2025 (%) Attrition in 2026 (%)
Southeast Asia 5.4 5.0 5.2 17.4 17.5 16.6
Indonesia 5.7 5.4 5.5 20.8 15.0 15.5
Malaysia 4.8 4.6 4.8 15.9 18.2 17.4
Philippines 5.3 5.0 5.3 19.1 20.0 17.3
Singapore 4.3 4.1 4.1 16.7 19.3 16.8
Thailand 4.6 4.5 4.6 16.6 17.2 16.4
Vietnam 7.7 6.6 6.7 15.5 15.0 16.2

Despite continued investment in talent, employee turnover remains a challenge across the region.

Attrition rates across all countries in the region were in double digits. Malaysia has the highest turnover rate at 17.4%, followed by the Philippines at 17.3% and Singapore at 16.8%. Attrition rates also vary by industry, with the consulting, business and community services industry having the highest attrition rate at 21.5%, followed by manufacturing at 17.9% and financial services at 17.7%.

Findings from Aon's 2026 Southeast Asia Talent Pulse Survey show that organisations are reallocating talent towards strategic business priorities. For companies with expansion plans, headcount growth is selective, with a focus on front-office roles (50%, including sales and revenue-generating roles) and engineering and technology roles (35%), while reductions will be targeted mainly at back-office operations roles among organisations with headcount contraction plans. The most in-demand roles are data and AI roles, at 64%, followed by front-office roles, at 56%, cybersecurity roles, at 44%, software and cloud roles, at 43%, including positions such as software and cloud engineers and project and programme management roles, at 41%.

"Workforce decisions have never been more complex, making access to reliable and defensible data essential for organisations," said Belinda Armenta, Head of Talent Data Solutions, Asia Pacific, Aon. "With AI accelerating change across industries, organisations are seeking deeper intelligence beyond historical benchmarks. Insights into compensation trends, workforce movements and talent risks enable leaders to make more informed decisions, helping them attract, retain and plan for the talent they need."

Aon conducted its 2026 Salary Increase and Turnover Study for Southeast Asia from July to September 2026, analysing the salary increase budgets and employee turnover rates among more than 1,200 businesses across Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam.

More information about Aon in Asia can be found here.

Hashtag: #Aon

The issuer is solely responsible for the content of this announcement.

About Aon

(NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that help protect and grow their businesses.

Follow Aon on , , and . Stay up-to-date by visiting Aon's and sign up for news alerts .

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

ROCHESTER, MINN., US / SINGAPORE – Media OutReach Newswire – 23 September 2026 – Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo's global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics. William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.

Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics. Mayo Clinic Laboratories and LifeStrands Genomics will work together to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia and New Zealand, with applications spanning the identification of genetic conditions, disease risk assessment, diagnosis, and treatment planning, enabling healthcare providers to integrate clinically relevant genomic insights into more personalised patient care.

LifeStrands Genomics will operate as "LifeStrands in collaboration with Mayo Clinic Laboratories" in certain markets, reflecting the organisations' shared commitment to expanding access to advanced genomic testing and precision medicine across the region.

Together, the organisations will pursue joint scientific initiatives, education and thought leadership to support the integration of genomics into patient care. "Healthcare providers across Southeast Asia, Australia and New Zealand are increasingly seeking advanced diagnostic solutions to guide patient care," said Dr. Morice. "Our collaboration with PAH and LifeStrands Genomics reflects our commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. Through this collaboration, we are bringing advanced diagnostic capabilities closer to patients and equipping healthcare providers with the insights needed to deliver personalised care."

"Mayo Clinic Laboratories' investment marks an important milestone in our relationship and a strong foundation for the next phase of diagnostic innovation across the region," Christopher Ting, M.D., founder and CEO of Pathology Asia Holdings, added. "Combining Mayo Clinic Laboratories' global clinical and scientific expertise with PAH's regional diagnostic capabilities and network will enable us to broaden access to advanced testing and increase access to genomics and precision medicine capabilities across Southeast Asia, Australia and New Zealand."

Hashtag: #MayoClinicLaboratories #PathologyAsia #LifeStrands #LifeStrandsGenomics #LifeStrandsGenomicsAustralia #DNALAB #DNALaboratories #PrecisionMedicine


The issuer is solely responsible for the content of this announcement.

Mayo Clinic Laboratories

Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for healthcare organisations worldwide in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services, delivering specialised diagnostic expertise to help healthcare providers make informed decisions and improve patient care.

Pathology Asia

Pathology Asia is a leading regional provider of pathology and laboratory diagnostics services, with operations across Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines and Australia. Its network encompasses established diagnostics brands including Innoquest, Singapore Diagnostics, TissuPath and Safework Health, as well as its specialist genomics businesses, LifeStrands Genomics and DNA Laboratories. Pathology Asia delivers a comprehensive range of pathology, molecular and genomic testing services to healthcare providers, hospitals and patients across the region through its network of internationally accredited laboratories.

LifeStrands Genomics

LifeStrands Genomics is a leading Asia-Pacific clinical genomics company comprising three specialist laboratories: LifeStrands Genomics Singapore, LifeStrands Genomics Australia, and DNA Laboratories. Together, the group provides advanced molecular and genomic testing across oncology, reproductive health, inherited disorders and wellness. Operating through CAP- and ISO 15189-accredited laboratories, LifeStrands Genomics delivers clinically actionable insights that empower healthcare professionals to make informed decisions, advance personalised care and improve patient outcomes.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

Recommended Articles